Functional vascular access evaluation after elective intervention for stenosis.
OBJECTIVE
To evaluate the functional effects of preventive vascular access (VA) intervention through periodic blood flow (Q A ) measurements during hemodialysis (HD) by the delta-H method.


METHODS
We prospectively monitored the blood flow rate (Q A ) of 100 VA (arteriovenous fistula (AVF) 81% or AV graft (AVG) 19%; mean VA duration 24.6 +/- 42.3 months) during HD in 89 end-stage renal disease patients (mean age 62.7 +/- 13.6 yrs; mean time on HD 30.9 +/- 43.9 months; 18% with diabetes) over a 3-yr period. Q A was measured at least every 4 months by the delta-H method (Yarar (6)) using the Crit Line III Monitor (overall mean Q A 1247.6 +/- 519.7 ml/min). The mean arterial pressure (MAP) and Kt/V index were measured simultaneously with Q A . Thirty-eight VA (38%) met the positive evaluation criteria (absolute Q A <700 ml/min 50%, Q A decreased >20% from baseline 50%). Most cases with positive evaluation underwent angiography (36/38, 95%) and had stenosis >/=50% (34/36, 94%). Of VA with significant stenosis, 17 (17/34, 50%) VA (AVF 76.5%, AVG 23.5%; mean VA duration 12.5 +/- 22.4 months, mean percentage of VA stenosis 75.8%) in 15 patients (mean age 68.4 +/- 9.8 yrs; mean time on HD 14.2 +/- 18.2 months; 33.3% with diabetes) underwent corrective intervention by angioplasty, 35.3% (6/17), and revision surgery, 64.7% (11/17).


RESULTS
Short-term results: Elective intervention was successful in 88% of treated VA (15/17). Mean Q A increased from 563.8 +/- 115.4 ml/min just before intervention (Q A pre) to 975.7 +/- 351.8 ml/min just after intervention (Q A post) (mean delta Q A = 411.8 +/- 290.1 ml/min) (p < 0.001). We found a significant difference between the overall mean Q A before (689.6 +/- 227.0 ml/min) vs after intervention (965.9 +/- 396.8 ml/min) (p = 0.011). No difference was found when the highest recorded mean Q A before intervention (877.7 +/- 415.4 ml/min) and mean Q A post were compared (p = 0.25). Mean MAP did not change after intervention (91.5 +/- 12.5 vs 92.7 +/- 14.2 mmHg, p = 0.46). Mean Kt/V index improved from 1.44 +/- 0.24 just before intervention to 1.49 +/- 0.23 just after intervention without any change in dialyzer type or HD duration (p = 0.025). Mean delta Q A was similar for diabetic patients vs non-diabetic patients (p = 0.34), for younger patients (age <65 yrs) vs older patients (age >/=65 yrs) (p = 0.64) and for AVF vs AVG (p = 0.39). We found a positive correlation between mean delta Q A and mean Q A post (r = 0.95, p < 0.001) or between mean delta Q A and overall mean Q A after intervention (r = 0.77, p < 0.001). Long-term results: Prevalence of VA thrombosis during the follow-up period (354.4 +/- 293.1 days): 17.6% (3/17). Five (29.4%) treated VA showed restenosis and two of them (40%) underwent reintervention by surgery. Mean restenosis period and mean decrease in Q A were 232.6 +/- 74.1 days and 2.8 +/- 0.6 ml/min/day, respectively. No significant correlation was found between mean delta Q A or Q A pre and mean restenosis period or decrease in Q A (p = ns).


CONCLUSIONS
1) Monitoring Q A by the delta-H method is useful in assessing the hemodynamic response to elective VA intervention. 2) Mean Q A post was similar to the highest recorded mean Q A before intervention. 3) Mean delta Q A was related to mean Q A post and overall mean Q A after intervention. 4) The HD effectiveness (Kt/V index) improved after intervention.
Roca-Tey
R
R
Department of Nephrology, Mollet Hospital, Barcelona, Spain. 18647rrt@comb.es
Samon
R
R
Ibrik
O
O
Martínes-Cercós
R
R
Viladoms
J
J
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D017130:Angioplasty; D001157:Arterial Occlusive Diseases / Q000209:etiology / Q000503:physiopathology* / Q000601:surgery; D001783:Blood Flow Velocity; D003251:Constriction, Pathologic; D017558:Elective Surgical Procedures; D005260:Female; D006801:Humans; D007201:Indicator Dilution Techniques; D007676:Kidney Failure, Chronic / Q000503:physiopathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome